Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. (Nasdaq: TCRX) is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for patients with cancer, with additional target discovery work in autoimmune disorders. The TCRX news page on Stock Titan aggregates company announcements, clinical updates, and regulatory disclosures so readers can follow how TScan’s programs evolve over time.
News coverage for TCRX often centers on the company’s hematologic malignancies program, particularly TSC-101 and the ALLOHA™ Phase 1 heme trial in patients with AML, ALL, or MDS undergoing allogeneic hematopoietic cell transplantation. Updates include clinical data readouts, such as relapse-free survival and overall survival observations, safety findings, and details on manufacturing process changes for TSC-101. Regulatory milestones, including alignment with the U.S. Food and Drug Administration on a pivotal trial design that mirrors the ALLOHA study, are also key topics in TScan’s press releases.
Investors and observers can also expect TCRX news about the PLEXI-T™ Phase 1 solid tumor trial, the company’s ImmunoBank of therapeutic TCRs, and its strategic decisions to prioritize the heme program while pausing further enrollment in the solid tumor trial. Additional updates highlight the development of in vivo-engineered TCR-T approaches for solid tumors, presentations at scientific meetings such as ASH, ASGCT, and ACR, and TargetScan-based discoveries in T cell-mediated autoimmune disorders.
Financial results, corporate strategy updates, workforce changes, and participation in investor conferences are reported through earnings releases and Form 8-K filings. By reviewing the TCRX news feed, readers gain context on TScan’s clinical progress, regulatory interactions, operational priorities, and research activities across oncology and autoimmunity.
TScan Therapeutics, focusing on T-cell receptor therapies for cancer, will have CEO David Southwell join a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Conference on October 5, 2021, at 2:00 p.m. ET. The chat will be accessible via live webcast on the company's website, with an archived replay available afterward. TScan is developing innovative treatments, including TSC-100 and TSC-101, targeting hematologic malignancies and various solid tumors.
TScan Therapeutics, Inc. (Nasdaq: TCRX) has appointed Zoran Zdraveski, J.D., Ph.D., as Chief Legal Officer. With over 20 years of experience in corporate law and business operations in the biopharmaceutical sector, Zdraveski is expected to significantly contribute to TScan’s efforts in advancing their T-cell receptor engineered therapies for cancer treatment. His expertise includes building intellectual property portfolios, which is crucial as TScan develops therapies targeting novel cancer antigens.
WALTHAM, Mass., Sept. 02, 2021 – TScan Therapeutics (Nasdaq: TCRX) announced that its CEO, David Southwell, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 4:15 p.m. ET. A live webcast of the event will be accessible on the company’s website, with an archived replay available post-event.
TScan Therapeutics focuses on developing T-cell receptor engineered therapies for cancer treatment, including TSC-100 and TSC-101 for hematologic malignancies.
TScan Therapeutics has debuted as a publicly traded company on Nasdaq under the ticker TCRX after raising $100 million in its IPO to fuel its TCR-T therapy programs for liquid and solid tumors. The company aims to submit IND applications for lead candidates TSC-100 and TSC-101 in Q4 2021, with clinical trials anticipated in H1 2022. Financial results show a net loss of $10.7 million for Q2 2021, up from $5.6 million in Q2 2020, but the cash position remains strong at $106.2 million, extending their runway into 2024.
TScan Therapeutics (Nasdaq: TCRX) announced advancements in next-generation SARS-CoV-2 vaccine research, focusing on T-cell targets discovered in recovering COVID-19 patients. Gavin MacBeath, Ph.D., will present these findings at the Cell-Mediated Therapies for Infectious Disease Summit on July 22, 2021. The research identified conserved epitope targets outside the Spike protein, showing promise in in vitro studies for second-generation vaccines. TScan has licensed these targets to QIAGEN and Poseida Therapeutics for further development of T-cell therapies and tests.
TScan Therapeutics announced the pricing of its initial public offering (IPO) on July 15, 2021, of 6,666,667 shares at a price of $15.00 each, raising $100 million before expenses. The offering will close around July 20, 2021, pending customary conditions. An additional 1,000,000 shares may be purchased by underwriters within 30 days. The stock is set to trade on Nasdaq under the symbol TCRX starting July 16, 2021. The company specializes in T-cell receptor-engineered therapies for cancer treatment.